Is TC BioPharm Stock a Good Investment?
TC BioPharm Investment Advice | TCBP |
- Examine TC BioPharm's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research TC BioPharm's leadership team and their track record. Good management can help TC BioPharm navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact TC BioPharm's business and its evolving consumer preferences.
- Compare TC BioPharm's performance and market position to its competitors. Analyze how TC BioPharm is positioned in terms of product offerings, innovation, and market share.
- Check if TC BioPharm pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about TC BioPharm's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in TC BioPharm Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if TC BioPharm Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine TC BioPharm Stock
Researching TC BioPharm's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. TC BioPharm Holdings recorded a loss per share of 192.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of August 2024.
To determine if TC BioPharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TC BioPharm's research are outlined below:
| TC BioPharm Holdings generated a negative expected return over the last 90 days | |
| TC BioPharm Holdings has high historical volatility and very poor performance | |
| TC BioPharm Holdings has some characteristics of a very speculative penny stock | |
| TC BioPharm Holdings has a very high chance of going through financial distress in the upcoming years | |
| TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| TC BioPharm Holdings has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Why TC Biopharm Stock Is Down Over 60 percent Today |
TC BioPharm Quarterly Liabilities And Stockholders Equity |
|
TC BioPharm uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in TC BioPharm Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to TC BioPharm's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know TC BioPharm's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TC BioPharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TC BioPharm Holdings backward and forwards among themselves. TC BioPharm's institutional investor refers to the entity that pools money to purchase TC BioPharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | Platform Technology Partners | 2024-09-30 | 0.0 | Sbi Securities Co Ltd | 2024-12-31 | 4.1 K | Gamma Investing Llc | 2024-12-31 | 1.2 K | Rhumbline Advisers | 2024-12-31 | 1.1 K | Harbour Investments, Inc. | 2024-12-31 | 236 | New England Capital Financial Advisors Llc | 2024-12-31 | 201 | Toth Financial Advisory Corp | 2024-12-31 | 30.0 | Signaturefd, Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Sanctuary Wealth Management, Llc | 2024-12-31 | 0.0 |
TC BioPharm's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 360.37 K.Market Cap |
|
TC BioPharm's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (3.92) | (4.11) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (2.53) | (2.40) |
Determining TC BioPharm's profitability involves analyzing its financial statements and using various financial metrics to determine if TC BioPharm is a good buy. For example, gross profit margin measures TC BioPharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TC BioPharm's profitability and make more informed investment decisions.
Evaluate TC BioPharm's management efficiency
TC BioPharm Holdings has return on total asset (ROA) of (1.0892) % which means that it has lost $1.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.1748) %, meaning that it created substantial loss on money invested by shareholders. TC BioPharm's management efficiency ratios could be used to measure how well TC BioPharm manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Tangible Assets is likely to drop to -0.67. In addition to that, Return On Capital Employed is likely to drop to -4.11. As of 03/24/2025, Total Current Liabilities is likely to grow to about 9.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 10 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | -3.3 K | -3.4 K | |
| Price Book Value Ratio | 82.59 | 86.71 | |
| Enterprise Value Multiple | (16.25) | (17.06) | |
| Price Fair Value | 82.59 | 86.71 | |
| Enterprise Value | 56.7 B | 53.8 B |
TC BioPharm's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.249 |
Basic technical analysis of TCBP Stock
As of the 24th of March, TC BioPharm owns the information ratio of (0.23), and Market Risk Adjusted Performance of 2.75. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TC BioPharm Holdings, as well as the relationship between them.TC BioPharm's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TC BioPharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on TC BioPharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TC BioPharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Randall Mark Edward over two weeks ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 | ||
Randall Diana Elizabeth over a month ago Acquisition by Randall Diana Elizabeth of 70000 shares of TC BioPharm subject to Rule 16b-3 | ||
Randall Kenneth Edward over a month ago Discretionary transaction by Randall Kenneth Edward of 5306464 shares of TC BioPharm at 4.25 subject to Rule 16b-3 | ||
Randall Mark Edward over six months ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 |
TC BioPharm's Outstanding Corporate Bonds
TC BioPharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TC BioPharm Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TCBP bonds can be classified according to their maturity, which is the date when TC BioPharm Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US878091BD86 Corp BondUS878091BD86 | View | |
| US878091BG18 Corp BondUS878091BG18 | View | |
| US878091BF35 Corp BondUS878091BF35 | View | |
| US878091BC04 Corp BondUS878091BC04 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand TC BioPharm's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing TC BioPharm's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | 2.75 | |||
| Mean Deviation | 7.84 | |||
| Coefficient Of Variation | (420.03) | |||
| Standard Deviation | 12.89 | |||
| Variance | 166.05 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (3.15) | |||
| Total Risk Alpha | (2.10) | |||
| Treynor Ratio | 2.74 | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (15.26) | |||
| Potential Upside | 13.65 | |||
| Skewness | (1.55) | |||
| Kurtosis | 10.24 |
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | 2.75 | |||
| Mean Deviation | 7.84 | |||
| Coefficient Of Variation | (420.03) | |||
| Standard Deviation | 12.89 | |||
| Variance | 166.05 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (3.15) | |||
| Total Risk Alpha | (2.10) | |||
| Treynor Ratio | 2.74 | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (15.26) | |||
| Potential Upside | 13.65 | |||
| Skewness | (1.55) | |||
| Kurtosis | 10.24 |
Consider TC BioPharm's intraday indicators
TC BioPharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of TC BioPharm stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
TC BioPharm time-series forecasting models is one of many TC BioPharm's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TC BioPharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
TCBP Stock media impact
Far too much social signal, news, headlines, and media speculation about TC BioPharm that are available to investors today. That information is available publicly through TCBP media outlets and privately through word of mouth or via TCBP internal channels. However, regardless of the origin, that massive amount of TCBP data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of TC BioPharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of TC BioPharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to TC BioPharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive TC BioPharm alpha.
TC BioPharm Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards TC BioPharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
TC BioPharm Corporate Management
| Michael MBA | CoFounder Chairman | Profile | |
| Lauren Bor | Head Division | Profile | |
| Martin Thorp | CFO Director | Profile | |
| Christopher Camarra | Executive Communications | Profile | |
| Bryan Kobel | CEO Director | Profile | |
| Angela Scott | CoFounder COO | Profile |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.